Literature DB >> 17087782

ApoA-I mutants V156K and R173C promote anti-inflammatory function and antioxidant activities.

K H Cho1, S H Park, J M Han, H C Kim, Y K Choi, I Choi.   

Abstract

BACKGROUND: Two mutants of apolipoprotein (apo) A-I, V156K and A158E, showed markedly different structural and functional properties in lipid-free and lipid-bound states in the authors' earlier report. The physiological activities of these mutants were compared with the wild-type (WT) and R173C mutant using in vitro and in vivo experiments.
MATERIALS AND METHODS: A reconstituted high-density lipoprotein (rHDL) with palmitoyloleoyl phosphatidylcholine (POPC), combined with each of the apoA-I variants, was injected into the tail-veins of hypercholesterolaemic mice (C57BL6/J), which had been fed a high cholesterol and high fat (HCHF; 0.5% cholesterol, 15% lard, 0.1% sodium cholate) diet for 23 weeks, once at 0 h and then every 24 h, at a dosage of 30 mg apoA-I kg(-1) of body-weight.
RESULTS: The V156K-rHDL and R173C-rHDL exhibited significantly stronger anti-oxidant activity against copper-mediated low-density lipoprotein (LDL) oxidation than did A158E in an apolipoprotein state. The mice injected with WT-rHDL or A158E-rHDL showed abrupt increases in total cholesterol concentrations (47% and 38%, respectively) as compared with the levels before injection, whereas the mice injected with V156K-rHDL and R173C-rHDL did not. Injection with V156K-rHDL improved serum lipids and anti-oxidative activities compared with the injection of WT-rHDL. Injection of WT-rHDL or A158E-rHDL increased serum interleukin-6 (IL-6) to 90-110 pg mL(-1), whereas the injection of V156K-rHDL or R173C-rHDL increased serum IL-6 to 17-25 pg mL(-1) only.
CONCLUSION: The V156K-rHDL and R173C-rHDL displayed potent beneficial effects, including anti-oxidant and anti-inflammatory activity from both in vitro and in vivo evaluations, whereas the WT-rHDL and A158E-rHDL did not.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17087782     DOI: 10.1111/j.1365-2362.2006.01737.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  8 in total

1.  Modified apolipoprotein (apo) A-I by artificial sweetener causes severe premature cellular senescence and atherosclerosis with impairment of functional and structural properties of apoA-I in lipid-free and lipid-bound state.

Authors:  Wookju Jang; Nam Ho Jeoung; Kyung-Hyun Cho
Journal:  Mol Cells       Date:  2011-04-21       Impact factor: 5.034

2.  Inhibition of collar-induced carotid atherosclerosis by recombinant apoA-I cysteine mutants in apoE-deficient mice.

Authors:  Xinbo Zhang; Xuewei Zhu; Baosheng Chen
Journal:  J Lipid Res       Date:  2010-09-03       Impact factor: 5.922

3.  Myocardial infarction patients show altered lipoprotein properties and functions when compared with stable angina pectoris patients.

Authors:  Kyung-Hyun Cho; Dong-Gu Shin; Suk-Hwan Baek; Jae-Ryong Kim
Journal:  Exp Mol Med       Date:  2009-02-28       Impact factor: 8.718

4.  A reconstituted HDL containing V156K or R173C apoA-I exhibited anti-inflammatory activity in apo-E deficient mice and showed resistance to myeloperoxidase-mediated oxidation.

Authors:  Kyung Hyun Cho; Jae Ryong Kim
Journal:  Exp Mol Med       Date:  2009-06-30       Impact factor: 8.718

5.  A proteoliposome containing apolipoprotein A-I mutant (V156K) enhances rapid tumor regression activity of human origin oncolytic adenovirus in tumor-bearing zebrafish and mice.

Authors:  Juyi Seo; Chae-Ok Yun; Oh-Joon Kwon; Eun-Jin Choi; Jae-Young Song; Inho Choi; Kyung-Hyun Cho
Journal:  Mol Cells       Date:  2012-07-30       Impact factor: 5.034

6.  Different Functional and Structural Characteristics between ApoA-I and ApoA-4 in Lipid-Free and Reconstituted HDL State: ApoA-4 Showed Less Anti-Atherogenic Activity.

Authors:  Jeong-Ah Yoo; Eun-Young Lee; Ji Yoon Park; Seung-Taek Lee; Sihyun Ham; Kyung-Hyun Cho
Journal:  Mol Cells       Date:  2015-05-22       Impact factor: 5.034

7.  Secondary structure changes in ApoA-I Milano (R173C) are not accompanied by a decrease in protein stability or solubility.

Authors:  Jitka Petrlova; Jonathan Dalla-Riva; Matthias Mörgelin; Maria Lindahl; Ewa Krupinska; Karin G Stenkula; John C Voss; Jens O Lagerstedt
Journal:  PLoS One       Date:  2014-04-22       Impact factor: 3.240

Review 8.  Antioxidative activity of high-density lipoprotein (HDL): Mechanistic insights into potential clinical benefit.

Authors:  Fernando Brites; Maximiliano Martin; Isabelle Guillas; Anatol Kontush
Journal:  BBA Clin       Date:  2017-08-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.